Catalent Inc. (NYSE:CTLT): The Most Important Numbers You Should Know

Catalent Inc. (NYSE:CTLT) has a beta of 1.47, a 12-month trailing P/E ratio of 57.98, and a growth ratio of 3.63. The stock’s Relative Strength Index (RSI) is 33.79, with weekly volatility at 4.33% and ATR at 4.34. The CTLT stock’s 52-week price range has touched low of $31.04 and a $127.68 high. Its shares traded lower over the last trading session, losing -4.88% on 03/04/21. The shares fell to a low of $101.935 before closing at $103.08. Intraday shares traded counted 1.36 million, which was -29.63% lower than its 30-day average trading volume of 1.05M. CTLT’s previous close was $108.37 while the outstanding shares total 170.23M.

Investors have identified the Drug Manufacturers – Specialty & Generic company Catalent Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $17.32 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Catalent Inc. (CTLT) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CTLT, the company has in raw cash 833.1 million on their books with 72.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 2.52 billion total, with 1.02 billion as their total liabilities.

Having a look at the company’s valuation, the company is expected to record 3.07 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CTLT sounds very interesting.

Is the stock of CTLT attractive?

In related news, SVP & Chief Financial Officer, Joseph Wetteny sold 5,000 shares of the company’s stock in a transaction that recorded on Feb 16. The sale was performed at an average price of 124.54, for a total value of 622,685. As the sale deal closes, the SVP & Chief Financial Officer, Joseph Wetteny now sold 4,604 shares of the company’s stock, valued at 523,613. Also, President, CSS, Whitlow Ricci S sold 692 shares of the company’s stock in a deal that was recorded on Jan 21. The shares were price at an average price of 118.85 per share, with a total market value of 82,244. Following this completion of acquisition, the Pres. Biologics & CCO, Flynn Karen now holds 2,478 shares of the company’s stock, valued at 278,279. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.

10 out of 13 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Catalent Inc.. 0 analysts has assigned a Sell rating on the CTLT stock. The 12-month mean consensus price target for the company’s shares has been set at $133.90.


Please enter your comment!
Please enter your name here